Skip to main content
AAPL-0.09%MSFT-0.01%NVDA-0.05%GOOGL-4.07%AMZN+0.05%TSM-6.34%SPCX-1.26%META-0.28%AVGO-3.92%TSLA-0.25%LLY-0.82%BRK-B-0.02%WMT+0.25%JPM-2.31%SKHY-7.29%AMD-5.58%MU+0.30%V+0.16%XOM-2.12%JNJ-1.12%MA+0.08%ASMLa-2.51%ABBV-0.16%COST+0.68%1398.HK+2.15%0700.HK+0.98%KO+0.23%CVX-1.23%PG+1.96%CSCO-1.17%UNH+1.12%ORCL-5.03%0939.HK+1.71%3988.HK+1.59%HD-0.34%BAC-1.84%GE-2.00%1816.HK+2.57%0857.HK+0.58%1288.HK+1.60%0005.HK+0.43%PM-1.47%HSBA.L-0.37%NVS-0.19%INTC-7.07%MS-2.65%AZN-0.23%AP2d-0.61%AMAT-5.47%TXN-3.09%AUDJPY-0.66%NZDJPY-0.65%AUDUSD-0.53%NZDUSD-0.48%GBPTRY+0.41%AUDCHF-0.41%NZDCHF-0.39%EURJPY-0.38%CADJPY-0.35%GBPJPY-0.34%AUDCAD-0.33%GBPHKD+0.32%GBPNZD+0.31%NZDCAD-0.31%GBPAUD+0.30%EURAUD+0.29%GBPMXN-0.28%EURNZD+0.27%CHFJPY-0.24%EURUSD-0.22%USDCAD+0.20%GBPUSD-0.18%USDJPY-0.17%USDILS+0.16%USDCHF+0.14%USDCNH-0.13%EURCHF-0.10%USDTRY+0.09%CADCHF-0.07%GBPCHF-0.04%AUDNZD-0.04%USDCOP-0.04%EURGBP-0.03%EURCAD-0.02%USDHKD+0.01%USDTHB-0.01%GBPCAD0.00%NOKJPY0.00%EURPLN0.00%NZDMXN0.00%GBPSGD0.00%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURSEK0.00%USDDKK0.00%CHFNOK0.00%EURNOK0.00%NZDSGD0.00%EURCZK0.00%EURDKK0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%USDMXN0.00%USDNOK0.00%USDSEK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD0.00%ETHUSD+56.78%USDTUSD-0.01%XRPUSD+54.01%SOLUSD+62.71%TRXUSDT+0.07%ZECUSDT-0.62%XMRUSDT-0.13%DOGEUSD+56.51%LINKUSD-1.38%XLMUSD-2.55%BCHUSDT-0.33%LTCUSD+46.82%UNIUSD-0.14%TONUSD+59.79%SUIUSD-1.69%HBARUSDT-2.70%TAOUSDT-1.62%AAVEUSD-1.55%ONDOUSDT-1.36%ICPUSDT+13.64%DOTUSDT-0.45%WLDUSDT-2.71%ARBUSDT-2.13%ATOMUSDT+2.17%INJUSDT-0.98%STXUSDT-2.35%PYTHUSDT-6.09%TIAUSDT-1.66%FETUSDT+0.63%SEIUSDT-0.49%JUPUSDT-7.90%OPUSDT-1.77%GRTUSDT-1.76%IOTAUSDT0.00%POLUSDT-1.87%WIFUSDT+1.46%AXSUSDT-1.60%EOSUSDT+0.66%FARTCOINUSDT-3.19%IMXUSDT-2.11%GALAUSDT-0.22%DYDXUSDT+0.48%ORDIUSDT-0.91%NOTUSDT+3.82%RONINUSDT-2.38%AAPL-0.09%MSFT-0.01%NVDA-0.05%GOOGL-4.07%AMZN+0.05%TSM-6.34%SPCX-1.26%META-0.28%AVGO-3.92%TSLA-0.25%LLY-0.82%BRK-B-0.02%WMT+0.25%JPM-2.31%SKHY-7.29%AMD-5.58%MU+0.30%V+0.16%XOM-2.12%JNJ-1.12%MA+0.08%ASMLa-2.51%ABBV-0.16%COST+0.68%1398.HK+2.15%0700.HK+0.98%KO+0.23%CVX-1.23%PG+1.96%CSCO-1.17%UNH+1.12%ORCL-5.03%0939.HK+1.71%3988.HK+1.59%HD-0.34%BAC-1.84%GE-2.00%1816.HK+2.57%0857.HK+0.58%1288.HK+1.60%0005.HK+0.43%PM-1.47%HSBA.L-0.37%NVS-0.19%INTC-7.07%MS-2.65%AZN-0.23%AP2d-0.61%AMAT-5.47%TXN-3.09%AUDJPY-0.66%NZDJPY-0.65%AUDUSD-0.53%NZDUSD-0.48%GBPTRY+0.41%AUDCHF-0.41%NZDCHF-0.39%EURJPY-0.38%CADJPY-0.35%GBPJPY-0.34%AUDCAD-0.33%GBPHKD+0.32%GBPNZD+0.31%NZDCAD-0.31%GBPAUD+0.30%EURAUD+0.29%GBPMXN-0.28%EURNZD+0.27%CHFJPY-0.24%EURUSD-0.22%USDCAD+0.20%GBPUSD-0.18%USDJPY-0.17%USDILS+0.16%USDCHF+0.14%USDCNH-0.13%EURCHF-0.10%USDTRY+0.09%CADCHF-0.07%GBPCHF-0.04%AUDNZD-0.04%USDCOP-0.04%EURGBP-0.03%EURCAD-0.02%USDHKD+0.01%USDTHB-0.01%GBPCAD0.00%NOKJPY0.00%EURPLN0.00%NZDMXN0.00%GBPSGD0.00%PLNJPY0.00%GBPZAR0.00%USDZAR0.00%USDPLN0.00%EURSEK0.00%USDDKK0.00%CHFNOK0.00%EURNOK0.00%NZDSGD0.00%EURCZK0.00%EURDKK0.00%CHFSGD0.00%SGDJPY0.00%AUDSGD0.00%USDMXN0.00%USDNOK0.00%USDSEK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%USDSGD0.00%GAGUSD0.00%W10.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD0.00%ETHUSD+56.78%USDTUSD-0.01%XRPUSD+54.01%SOLUSD+62.71%TRXUSDT+0.07%ZECUSDT-0.62%XMRUSDT-0.13%DOGEUSD+56.51%LINKUSD-1.38%XLMUSD-2.55%BCHUSDT-0.33%LTCUSD+46.82%UNIUSD-0.14%TONUSD+59.79%SUIUSD-1.69%HBARUSDT-2.70%TAOUSDT-1.62%AAVEUSD-1.55%ONDOUSDT-1.36%ICPUSDT+13.64%DOTUSDT-0.45%WLDUSDT-2.71%ARBUSDT-2.13%ATOMUSDT+2.17%INJUSDT-0.98%STXUSDT-2.35%PYTHUSDT-6.09%TIAUSDT-1.66%FETUSDT+0.63%SEIUSDT-0.49%JUPUSDT-7.90%OPUSDT-1.77%GRTUSDT-1.76%IOTAUSDT0.00%POLUSDT-1.87%WIFUSDT+1.46%AXSUSDT-1.60%EOSUSDT+0.66%FARTCOINUSDT-3.19%IMXUSDT-2.11%GALAUSDT-0.22%DYDXUSDT+0.48%ORDIUSDT-0.91%NOTUSDT+3.82%RONINUSDT-2.38%
VI

Viatris Inc. (VTRS)

NASDAQ • Healthcare

$20.74
-$0.08 (-0.4%)
Market closed

Last close at November 16, 2026 at 21:00 UTC

Open$20.89
Day Range$20.61 - $20.98
Avg. Volume (3M)9.4M
Market Cap$23.7B
52 Week Range
$10.15$21.2

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$3.7B100%
Gross Profitminus cost of goods$1.4B38%
Operating Incomeminus R&D and overhead$261.5M7%

In plain terms: out of every $100 in revenue, Viatris Inc. currently loses $9.

Fundamentals & Financials

Revenue (TTM)
$14.7B
Net Income (TTM)
-$607.8M
EPS (TTM)
-$0.53
ROA (TTM)
-1.75%
Current Ratio
1.55
Dividend Yield
0.68%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+17.5%Q2 2026$0.59
+14.8%Q3 2026$0.69
+11.5%Q4 2026$0.71

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Beat +11.5%

Viatris topped EPS expectations while revenue came in line in the third fiscal quarter of 2026, reported November 5, 2026, with adjusted EPS of $0.71 topping the $0.64 estimate (+11%) even as revenue of $3.749 billion was in line with a $3.786 billion estimate (-0.96%). On a year-over-year basis, revenue slipped ~0% to roughly $3.7 billion from about $3.8 billion a year ago, while gross profit was about $1.4 billion and gross margin stood near 38%. The quarter’s GAAP net loss widened to roughly $325 million (down -153.7% year over year) versus a net loss of about $128 million a year ago. Viatris generated about $899 million of operating cash flow, and it returned cash through roughly $150 million of share repurchases alongside about $138 million paid in dividends. For the next period, consensus calls for EPS of $0.60 on revenue of $3.719 billion.

View full earnings history

About Viatris Inc.

Viatris Inc. operates in healthcare as a maker of branded, generic, and specialty medicines, trading on NASDAQ under VTRS. Its portfolio spans treatments from Lyrica and Lipitor to biosimilars and raw pharmaceutical ingredients, and it generated $14.3 billion of revenue in FY2025.

Name
Viatris Inc.
CEO
Scott Andrew Smith
Industry
Healthcare
Year Founded
1961
Employees
30,000

Today's Snapshot

AI-generated

The day ended with VTRS slightly lower at 20.74, in line with a flat sector. Shares changed hands at about two-thirds of its usual level. Viatris agreed to become a pharmaceutical partner of Cadillac’s Formula 1 team from 2027.

Trading Volume

Below 10d avg (10.3M)

7.1M

vs S&P 500 Today

Outperforming Market

+1.52%

Updated: November 16, 2026 at 21:25 UTC

Technical Indicators

6 Buy1 Neutral1 Sell
VTRS is showing a robust technical posture as the price near 20.74 sits well above the major moving averages, reflecting a sustained uptrend while ADX (about 36.6) signals strong directional strength. Momentum measures are supportive — MACD and CCI are bullish and RSI is firm rather than overbought — and on-balance volume confirms bullish participation. Volatility is modest, with a low ATR and Bollinger readings suggesting contained swings, and the classic pivot sits near the current price as a short-term reference. Technical takeaway: trend, momentum and volume align with a strong buy stance.
All signals
  • EMA (5 indicators)$16.14 - $20.25
    Buy
  • RSI (14)68.78
    Neutral
  • Stochastic %K (14, 3, 3)84.51
    Sell
  • MACD Level (12, 26)0.79
    Buy
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.